World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
56380
World Ranking
4180
National Ranking
161

Hans Gelderblom publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hans Gelderblom sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 831 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hans Gelderblom D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hans Gelderblom sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 117 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hans Gelderblom is affiliated with Leiden University Medical Center in the Netherlands, specializing in medical research with a focus on oncology and related subfields. Their academic output spans a broad spectrum within medicine, with notable concentration in pulmonary and respiratory medicine, oncology, rheumatology, gastroenterology, and surgery.

Their research portfolio prominently features sarcoma diagnosis and treatment alongside gastrointestinal tumor research and treatment. Additional areas of expertise include gastric cancer management and outcomes, musculoskeletal synovial abnormalities and treatments, cancer genomics and diagnostics, cardiac tumors and thrombi, as well as bone tumor diagnosis and treatments.

Gelderblom's work has been published extensively in various scientific journals. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Cancers
  • ESMO Open

Key recent publications reflect collaboration in clinical guidelines and rigorous clinical trials in oncology, including:

  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial, 2020, The Lancet Oncology
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Collaboration is a significant aspect of Gelderblom's research, with frequent coauthors including:

  • Jean-Yves Blay
  • Michiel A. J. van de Sande
  • Robin L. Jones
  • Silvia Stacchiotti
  • Sebastian Bauer

Best Publications

  • Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

    Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Combination Chemotherapy in Advanced Adrenocortical Carcinoma

    Martin Fassnacht;Massimo Terzolo;Bruno Allolio;Eric Baudin

  • The Clinical Approach Towards Chondrosarcoma

    Hans Gelderblom;Pancras C.W. Hogendoorn;Sander D. Dijkstra;Carla S. van Rijswijk

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;J.-Y. Blay

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

    Jakob K. Anninga;Hans Gelderblom;Marta Fiocco;Judith R. Kroep

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

  • Clinical pharmacokinetics of tyrosine kinase inhibitors.

    Nielka P. van Erp;Hans Gelderblom;Henk-Jan Guchelaar

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

    Alex Sparreboom;Lia van Zuylen;Eric Brouwer;Walter J. Loos

  • Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    A. Berruti;E. Baudin;H. Gelderblom;H. R. Haak

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

Frequent Co-Authors

Henk-Jan Guchelaar
Henk-Jan Guchelaar Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Peter Hohenberger
Peter Hohenberger Heidelberg University
Judith V.M.G. Bovée
Judith V.M.G. Bovée Leiden University Medical Center
Pancras C.W. Hogendoorn
Pancras C.W. Hogendoorn Leiden University Medical Center
Alessandro Gronchi
Alessandro Gronchi University of Milan
Paolo G. Casali
Paolo G. Casali University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens doors to a wide range of related online degrees and specialties. Many students interested in healthcare opt for the cheapest online health science degree options to gain foundational knowledge while keeping tuition costs manageable.

For those considering a leadership role, the most affordable mha programs prepare graduates for management positions in healthcare settings. If your goal is advanced clinical practice, there are also cheapest bsn to dnp programs available online, streamlining the journey to a Doctor of Nursing Practice.

Pharmacy is another in-demand branch. Today, it’s possible to earn an online pharmacy degree from accredited institutions, offering more flexibility for aspiring pharmacists. These online programs help students balance career advancement with personal commitments, making them valuable pathways for those pursuing healthcare careers beyond the traditional MD route.

Best Scientists Citing Hans Gelderblom

Trending Scientists

Recently Published Articles